摘要
以鹅去氧胆酸(CDCA)和牛磺酸为基本原料合成了牛磺鹅去氧胆酸钠(TCDCANa),以萃取和重结晶法提纯,收率63.4%,w(TCDCANa)≥92%,以TLC和IR法确定了其结构。并将牛磺鹅去氧胆酸钠与鹅去氧胆酸钠(CDCANa)进行了抗菌、抗炎和镇咳对比实验。药效实验结果为:TCDCANa和CDCANa均具有抗革兰阳性菌作用(抑菌环直径分别为2.46±0.08cm和1.91±0.13cm),抗炎作用抑制率分别为(79.1±25.4)%和(71.2±23.1)%,镇咳作用减咳率分别为(29.1±5.6)%和(18.2±6.8)%,牛磺鹅去氧胆酸钠与鹅去氧胆酸钠间存在显著性差异。药效实验表明,TCDCANa具明显的镇咳、平喘和抗菌作用,其作用强于CDCANa。
The sodium taurochenodeoxycholate （TCI）CANa） was prepared by conjugating staring compound chenodeoxycholie acid with taurine, and purified by means of extraction and recrystallization. The yield of TCDCANa was 63.4% and purity w （TCDCANa） ≥92%. Its structure was confirnted by TLC and IR. Antibacterial test, anti-inflammatory test and antitussive test were made. With TCDCANa and sodium chenodeoxycholate （CDCANa）, the results of phannacodynamics are respectively：dlameter of bacterial inhibition zone （2.46 ±0.08 ） and （ 1.91 ± 0. 13 ） cm, rate of inhibition （79.1 ± 25.4） % and （71.2 ± 23. 1 ） % , and antitussive rate （29.1± 5.6） % and （ 18.2 ± 6.8） %. There are significant differences in all those data between TCDCANa and CDCANa （P 〈 0.01 ）. It is proved that TCDCANa has more evident antibacterial, anti-inflammatory and antitussive effects than CDCANa.
出处
《精细化工》
EI
CAS
CSCD
北大核心
2007年第11期1087-1090,共4页
Fine Chemicals
基金
国家科学基金项目(No:30160083)
华中科技大学同济医学院基金项目(No:00MY21-30)
华中科技大学基金项目(No:02022Y-12)~~
关键词
牛磺鹅去氧胆酸
抗菌
抗炎
中药现代化
taurochenodeoxycholic acid
antibacterial
anti-inflammatory
modernization of Chinese medicine
